My app is screaming at me to look into $CATX
"Negative enterprise value provides deep asymmetry against strong Phase 2 ESMO NET data"
2
7
860
$LQDA took 6% positon last week and should have allocated more. Everything else took a hit and left me overextended.
1
6
615
$VRDN
Last week, Innovent dropped Phase 3 data for Sycume and Sling Therapeutics revealed numbers for its oral small molecule, Linsitinib. Enspryng may get FDA approval this week, too.
It may look as if the Thyroid Eye Disease (TED) space is suddenly crowded.
It isn't.
The entire field is fighting over active disease where modest anti-inflammatory gains are routinely mistaken for efficacy. Meanwhile, they're leaving the other 80% of the market (Chronic TED) entirely to one biotech.
Chronic TED patients do not have red, painful eyes. They have fixed, disfiguring proptosis and debilitating double vision (diplopia) driven by scarred, fibrosed extraocular rectus muscles and mature retro-orbital fat. Until now, their only real option was invasive, multi-wall orbital decompression surgery, which offers little diplopia relief and often worsens it.
Chronic TED is a structural disease requiring potent, sustained tissue remodeling. Let's look at every drug available/in pipeline.
Enspryng (satralizumab)
IL-6 signaling is silent in an inactive orbit (CAS 0–1). It has zero mechanism to clear cross-linked collagen or mature adipocytes.
Satralizumab is irrelevant in inactive TED.
Linsitinib
Oral TKIs lack the sustained receptor occupancy required to remodel fibrosed tissue. Even in active disease, its only viable dose (150 mg BID) carried a 33.3% discontinuation rate from GI toxicity and transaminase spikes. Sling Therapeutics was smart to skip chronic TED entirely.
Lastly SYCUME
An amino acid clone of Tepezza. It achieved a modest -1.00 mm in placebo subtracted proptosis reduction and delivered no meaningful signal in chronic diplopia and it validates the shortcomings we already know about Tepezza.
Tepezza currently pulls in close to $100 million per quarter from chronic TED patients despite carrying a heavy exposure burden and zero diplopia benefit.
Viridian Therapeutics now has the only portfolio that genuinely treats them and that's the differentiation.
This Dr. puts it nicely. instagram.com/reel/DePaIogof…
Took a small position in $IVA
Potential 2 to 4x upside if the Phase 3 NATiV3 topline results replicate Phase 2b efficacy signals. Readout expected before end of this year.
1/3
Watching $ANNX
Intravitreal C1q-targeting Fab engineered to halt synaptic pruning and protect photoreceptor integrity, targeting functional vision preservation rather than anatomical lesion slowing
1/3
1
4
1,128
In the Phase 2 ARCHER trial (n=270), ANX007 achieved 72% relative risk reduction in persistent ≥15-letter visual acuity loss at Month 12 (p=0.006) and 59% at Month 24 on monthly dosing, despite missing statistical significance on slowing GA lesion area expansion
2/3
1
259
$PCVX
At ~$8.4B Market cap, the stock already prices in substantial Phase 3 success
investors.vaxcyte.com/news-r…
2
4
2,085
Stalking $AVTX - Hidradenitis Suppurativa
Most standard and late stage pipeline therapies target the TNF alpha or IL-17 pathways (They only downregulate downstream parts of the immune system)
AVTX-009 targets Interleukin 1 beta and it is much higher up.
1/2
1
6
904
AVTX-009 could potentially prevent permanent scarring and tissue destruction, rather than just masking the inflammation and controlling surface flareup.
$AVTX
2/2
4
332
How biotech sector in general works especially for small cap stocks with good fundamentals.
This is not a one stock related but most goes through a cycle of euphoria➡️Doom and Gloom➡️Euphoria and cycle repeats.
Flush stock price down on positive or no news➡️ Create uncertainty among retail folks ➡️ weak hands sell despite good due diligence. Stock makes a base, and trade sideways for extended period of time before making a big upside.
$VRDN is running a new phase 4 trial testing Lumvoa specifically for patients who previously responded to teprotumumab but subsequently had a disease recurrence.
Relapsed segment itself a multibilion opportunity clinicaltrials.gov/study/NCT…
2
8
1,364
OldGrape retweeted
This is a biotech bear market crammed into a single month. $xbi
$KYTX
Clean confirmation that this one time therapy is durable
Median T25FW improvement was 46% at week 16 and 49% at month 12, and 95% of patients who hit a clinically meaningful improvement at the primary analysis kept it. 92% remained free of chronic immunotherapies for SPS
So 4000 patients readily available. That's few billion dollars.
Current $200 million cash enough until 2028 and SPS will generate enough money to fund Generalized myasthenia gravis (gMG) and progressive MS trials
$KYTX
2
2
513
Progressive multiple sclerosis: FDA gave miv-cel RMAT designation in non-active secondary progressive MS, based on investigator-led trials at Stanford and UCSF.
Progressive MS has almost nothing that works.
$KYTX
1
3
484










